Galvani Bioelectronics
Galvani Bioelectronics is a UK-based bioelectronics company founded in 2016 that develops implantable neural interface therapies to treat chronic illnesses by modulating electrical signals in the nervous system, combining hardware, wireless power, and AI signal processing.
- Company typePrivate
- Founded2016
- HeadquartersStevenage, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Galvani Bioelectronics does
Galvani Bioelectronics is a UK-based bioelectronics company founded in 2016 and headquartered in Stevenage. The firm is developing therapeutic approaches that treat chronic illnesses by modulating electrical impulses in the body's nervous system. Its work sits at the intersection of neuroscience, device engineering, and clinical medicine, targeting conditions addressable through electrical neuromodulation rather than pharmacological intervention.
The company's core platform is built around implantable neural interface (INI) technology, combining high-channel-count hardware, wireless power delivery, closed-loop stimulation, and AI-assisted signal processing. This architecture is designed to enable minimally invasive deployment and adaptive therapy for chronic diseases. The company operates with a small team (11-50 employees) and has assembled leadership spanning clinical medicine, executive management, and principal engineering, reflecting the multi-disciplinary demands of bioelectronic therapy development.
Commercial revenue, pricing, distribution channels, and customer segments are not disclosed in available sources, indicating a pre-commercial, research-and-development-stage posture consistent with the long regulatory and clinical timelines typical of implantable medical devices. The global bioelectric medicine market is projected to grow from USD 25.48 billion in 2025 to USD 47.28 billion by 2034 (CAGR ~7.12%), providing the macro tailwind in which the company is positioned.
Galvani Bioelectronics firmographics
Firmographics- Name
- Galvani Bioelectronics
- Website
- https://galvani.bio
- Company type
- Private
- Founded year
- 2016
- Headcount range
- 11–50 employees
- Short description
- Galvani Bioelectronics is a UK-based bioelectronics company founded in 2016 that develops implantable neural interface therapies to treat chronic illnesses by modulating electrical signals in the nervous system, combining hardware, wireless power, and AI signal processing.
- Ownership category
- akta.pro rank
Galvani Bioelectronics industry classification
Industry- Product category
- Bioelectronic Medicine
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
- akta.pro secondary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Galvani Bioelectronics is headquartered
LocationHeadquarters
- HQ city
- Stevenage
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Galvani Bioelectronics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Galvani Bioelectronics product offering
Product offeringCore offering
Galvani Bioelectronics develops bioelectronic medicines designed to treat chronic illnesses by controlling electrical impulses in the body. The company focuses on implantable neural interface technology that reads and modulates nerve signals to address disease pathways, with the goal of providing targeted, device-based therapies for chronic conditions.
Differentiator
Problem solved
Functional benefit
Companies that use Galvani Bioelectronics
Customer profileIdeal customer profiles1 record
Galvani Bioelectronics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Galvani Bioelectronics partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Expansion highlights3 records
Galvani Bioelectronics competitors and assessment
Company assessmentDirect peers
- Nevro Corp: Nevro develops implantable spinal cord stimulation systems for chronic pain, making it a direct peer in implantable neuromodulation with overlapping clinical targets and a similar hardware-plus-software therapy model.
- Axonics: Axonics manufactures implantable sacral neuromodulation systems for incontinence, a direct peer in miniaturized, rechargeable implantable neurostimulators targeting chronic disease indications.
- Saluda Medical: Saluda Medical develops closed-loop spinal cord stimulation systems, making it one of the closest direct peers given Galvani's emphasis on closed-loop stimulation and AI-driven signal processing.
- setPoint Medical: setPoint Medical is developing implantable vagus nerve stimulation therapies for inflammatory and autoimmune diseases, a direct peer in bioelectronic medicine targeting chronic conditions beyond pain.
- ElectroCore: ElectroCore develops non-invasive vagus nerve stimulation, a closely related peer in bioelectronic/neuromodulation therapies for chronic conditions, though differentiated by its non-invasive delivery.
Emerging players
- Cala Health: Cala Health develops wearable neuromodulation devices for chronic disease, an emerging peer that intersects with Galvani's bioelectronic therapy approach but with a non-implantable delivery model.
Broad incumbents
- Medtronic: Medtronic operates the largest portfolio of implantable neuromodulation devices (SCS, DBS, VNS, intrathecal), making it the dominant broad incumbent against which Galvani must differentiate.
- Abbott: Abbott's Neuromodulation business (formerly St. Jude Medical) markets leading spinal cord and dorsal root ganglion stimulation systems, a broad incumbent with deep clinical and commercial reach.
- Boston Scientific: Boston Scientific markets the Precision and Spectra spinal cord stimulation platforms alongside deep brain stimulation systems, a broad incumbent competing across most implantable neuromodulation indications.
- LivaNova: LivaNova is a leading manufacturer of vagus nerve stimulation therapy for drug-resistant epilepsy and depression, a broad incumbent that overlaps directly with Galvani's bioelectronic VNS therapy direction.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Galvani Bioelectronics social profiles
Digital presenceGalvani Bioelectronics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Galvani Bioelectronics leadership team
Management profileNumber of profiles
Profiles3 records
Galvani Bioelectronics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Galvani Bioelectronics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Galvani Bioelectronics
What does Galvani Bioelectronics do?
Galvani Bioelectronics develops bioelectronic medicines designed to treat chronic illnesses by controlling electrical impulses in the body. The company focuses on implantable neural interface technology that reads and modulates nerve signals to address disease pathways, with the goal of providing targeted, device-based therapies for chronic conditions.
When was Galvani Bioelectronics founded?
Galvani Bioelectronics was founded in 2016. It employs 11 to 50 people.
Where is Galvani Bioelectronics based?
Galvani Bioelectronics is headquartered in Stevenage, United Kingdom, in the Europe region.
Who are Galvani Bioelectronics's main competitors?
Direct peers on record are Nevro Corp, Axonics, Saluda Medical, setPoint Medical and ElectroCore. Cala Health is listed as an emerging player. Broad incumbents are Medtronic, Abbott, Boston Scientific and LivaNova.
Does Galvani Bioelectronics have an API?
No public API is recorded for Galvani Bioelectronics.
What industry is Galvani Bioelectronics in?
Galvani Bioelectronics's product category is Bioelectronic Medicine. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 334510 and its SIC code is 3845.